Stephen Sondheim by Daniel Okrent review – a superb biography of the musical master Packed with gossip and incident, this book is also a fascinating study in the gestation of genius The Guardian - UK · May 21
MindMed's Q3 2022 Financials & Business, Setting The Stage For Phase 3 Trials Clinical-stage biotech company Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) reported its financial results and updated on its programs pipeline of the third quarter ended September 30, 2022. Benzinga · Nov 11, 2022
Miami clinic kicks off first national study of LSD, once a ‘public enemy,’ to treat anxiety MIAMI — The gurus of the psychedelic era of American pop culture extolled the experience of the “acid trip.” But the U.S. government and much of the public remained leery of LSD, with President Richard Nixon declaring it and assorted other drugs “public enemy No. 1.” Miami Herald · Sep 22, 2022
MindMed: Financial And Business Results For Q2 2022, Management And Pipeline Changes MindMed (NASDAQ: MNMD), which recently received a letter on behalf of one of its shareholders calling for a new business strategy and offer Benzinga · Aug 12, 2022
Pro-Patient Psychedelic Treatments Are Finally Moving Forward In A 'New Paradigm Shift' Last week, Benzinga’s Psychedelics Capital Conference brought a premier gathering of the biggest publicly traded psychedelics companies in North America with forward-thinking investors to Miami, where the hottest topic seemed to revolve around LSD and derivative molecules. Benzinga · Apr 26, 2022
Psyched: Atai, MindMed, Enveric and Mydecine Release 2021 Earnings, Bienstar Expands To Brazil & More! It’s earnings week in the psychedelics space, opening a new window into the financial situations of many companies in the sector. Benzinga · Apr 6, 2022
MindMed Appoints Francois Lilienthal As New CCO With over twenty years of experience in the biopharmaceutical industry, Francois Lilienthal, MD, has joined Mind Medicine Inc. (NASDAQ:MNMD) as chief commercial officer (CCO). He had been serving as a consultant for the company for the last six months. Lilienthal has a long trajectory with pharmaceutical companies—in 1997, he was… Benzinga · Apr 5, 2022
From Pharma To Psychedelics, Robert Barrow, CEO Of MindMed: Meet Our Speakers With over ten years of experience in the pharmaceutical industry, Robert Barrow, CEO of Mind Medicine Inc. (NASDAQ:MNMD) is someone who certainly knows the ins and outs of the business. Barrow joined MindMed in January 2021 as Chief Development Officer (CDO) but was later appointed as CEO and member of… Benzinga · Apr 5, 2022